These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1008 related articles for article (PubMed ID: 21622720)

  • 1. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.
    Zhang QY; Tao SY; Lu C; Li JJ; Li XM; Yao J; Jiang Q; Yan B
    Mol Med Rep; 2020 Jun; 21(6):2571-2579. PubMed ID: 32323773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L
    Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Realgar transforming solution suppresses angiogenesis and tumor growth by inhibiting VEGF receptor 2 signaling in vein endothelial cells.
    Song P; Hai Y; Wang X; Zhao L; Chen B; Cui P; Xie Q; Yu L; Li Y; Wu Z; Li H
    Arch Pharm Res; 2018 Apr; 41(4):467-480. PubMed ID: 29542005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
    Saraswati S; Kumar S; Alhaider AA
    Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.
    Shen G; Li Y; Du T; Shi G; Dai L; Chen X; Zheng R; Li W; Su X; Zhang S; Wei Y; Yang S; Deng H
    Neoplasma; 2012; 59(5):486-93. PubMed ID: 22668017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
    Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
    J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
    PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raddeanin A, a triterpenoid saponin isolated from Anemone raddeana, suppresses the angiogenesis and growth of human colorectal tumor by inhibiting VEGFR2 signaling.
    Guan YY; Liu HJ; Luan X; Xu JR; Lu Q; Liu YR; Gao YG; Zhao M; Chen HZ; Fang C
    Phytomedicine; 2015 Jan; 22(1):103-10. PubMed ID: 25636878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
    Nicoli S; Ribatti D; Cotelli F; Presta M
    Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY; Pan YM; Chen ZW; Lin Y; Wang LH; Chen YH; Jie TT; Lu YY; Liu JC
    J Ethnopharmacol; 2013 Apr; 146(3):724-33. PubMed ID: 23434607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
    Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
    Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.